Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZR2 Regimen in Elderly Treatment-naive DLBCL
NCT04460248Phase 2Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Primary completion
- Feb 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Started Aug 2020; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04460248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04460248.